0001209191-18-011662.txt : 20180220 0001209191-18-011662.hdr.sgml : 20180220 20180220202207 ACCESSION NUMBER: 0001209191-18-011662 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180215 FILED AS OF DATE: 20180220 DATE AS OF CHANGE: 20180220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciechanover Isaac E. CENTRAL INDEX KEY: 0001612096 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 18626717 MAIL ADDRESS: STREET 1: C/O ATARA BIOTHERAPEUTICS, INC. STREET 2: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-15 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001612096 Ciechanover Isaac E. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 Chief Executive Officer Common Stock 2018-02-15 4 S 0 2500 45.58 D 260378 I See footnote Common Stock 2018-02-15 4 S 0 2433 46.71 D 257945 I See footnote Common Stock 2018-02-15 4 S 0 4767 47.56 D 253178 I See footnote Common Stock 2018-02-15 4 S 0 300 48.25 D 252878 I See footnote Common Stock 2018-02-16 4 S 0 3000 45.44 D 249878 I See footnote Common Stock 2018-02-16 4 S 0 1600 46.55 D 248278 I See footnote Common Stock 2018-02-16 4 S 0 5100 47.91 D 243178 I See footnote Common Stock 2018-02-16 4 S 0 300 48.43 D 242878 I See footnote Common Stock 2018-02-15 4 M 0 3938 0.00 A 812613 D Restricted Stock Units 2018-02-15 4 M 0 3938 0.00 D Common Stock 3938 0 D Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.10 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.15 to $48.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.15 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.25 to $48.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $48.30 to $48.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Shares issued upon settlement of vested restricted stock units ("RSUs"). Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. Fully vested. The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. /s/ David Tucker, Attorney-in-Fact for Isaac E. Ciechanover 2018-02-20